{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T10:05:09Z","timestamp":1768557909070,"version":"3.49.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,6,6]],"date-time":"2011-06-06T00:00:00Z","timestamp":1307318400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Reovirus type 3 Dearing (T3D) has demonstrated oncolytic activity <jats:italic>in vitro<\/jats:italic>, in <jats:italic>in vivo<\/jats:italic> murine models and in early clinical trials. However the true potential of oncolytic viruses may only be realized fully in combination with other modalities such as chemotherapy, targeted therapy and radiotherapy. In this study, we examine the oncolytic activity of reovirus T3D and chemotherapeutic agents against human prostate cancer cell lines, with particular focus on the highly metastatic cell line PC3 and the chemotherapeutic agent docetaxel. Docetaxel is the standard of care for metastatic prostate cancer and acts by disrupting the normal process of microtubule assembly and disassembly. Reoviruses have been shown to associate with microtubules and may require this association for efficient viral replication.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The effects of reovirus and chemotherapy on <jats:italic>in vitro<\/jats:italic> cytotoxicity were investigated in PC3 and Du 145 cells and the interactions between agents were assessed by combination index analysis. An Annexin V\/propidium iodide fluorescence-activated cell sorting-based assay was used to determine mode of cell death. The effects of reovirus and docetaxel administered as single agent or combination therapy were tested <jats:italic>in vivo<\/jats:italic> in a murine model. The effects of docetaxel and reovirus, alone and together, on microtubule stabilisation were investigated by Western blot analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Variable degrees of synergistic cytotoxicity were observed in PC3 and Du 145 cells exposed to live reovirus and several chemotherapy agents. Combination of reovirus infection with docetaxel exposure led to increased late apoptotic\/necrotic cell populations. Reovirus\/docetaxel combined therapy led to reduced tumour growth and increased survival in a PC3 tumour bearing mouse model. Microtubule stabilization was enhanced in PC3 cells treated with reovirus\/docetaxel combined therapy compared to other reovirus\/chemotherapy combinations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The co-administration of a variety of chemotherapeutic agents with live reovirus was able to enhance cytotoxicity synergistically <jats:italic>in vitro<\/jats:italic>. The combination of docetaxel with reovirus also delayed tumour growth and improved survival <jats:italic>in vivo<\/jats:italic>. Enhanced microtubule stabilisation following this combination treatment may, in part, explain the mechanism of synergy. These results provide evidence to support the ongoing clinical trials using these agents.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-11-221","type":"journal-article","created":{"date-parts":[[2011,6,7]],"date-time":"2011-06-07T06:27:20Z","timestamp":1307428040000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer"],"prefix":"10.1186","volume":"11","author":[{"given":"Lucy","family":"Heinemann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy R","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Boxall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Kottke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate L","family":"Relph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Vile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Melcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Prestwich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin J","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hardev S","family":"Pandha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,6,6]]},"reference":[{"key":"2716_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/BF01314776","volume":"54","author":"G Hashiro","year":"1977","unstructured":"Hashiro G, Loh PC, Yau JT: The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol. 1977, 54: 307-15. 10.1007\/BF01314776.","journal-title":"Arch Virol"},{"key":"2716_CR2","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1128\/jvi.28.2.444-449.1978","volume":"28","author":"MR Duncan","year":"1978","unstructured":"Duncan MR, Stanish SM, Cox DC: Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol. 1978, 28: 444-9.","journal-title":"J Virol"},{"key":"2716_CR3","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1126\/science.282.5392.1332","volume":"282","author":"MC Coffey","year":"1998","unstructured":"Coffey MC, Strong JE, Forsyth PA, Lee PW: Reovirus therapy of tumors with activated Ras pathway. Science. 1998, 282: 1332-4.","journal-title":"Science"},{"key":"2716_CR4","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1093\/emboj\/17.12.3351","volume":"17","author":"JE Strong","year":"1998","unstructured":"Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW: The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J. 1998, 17: 3351-62. 10.1093\/emboj\/17.12.3351.","journal-title":"EMBO J"},{"key":"2716_CR5","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1128\/jvi.70.1.612-616.1996","volume":"70","author":"JE Strong","year":"1996","unstructured":"Strong JE, Lee PW: The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol. 1996, 70: 612-6.","journal-title":"J Virol"},{"key":"2716_CR6","first-page":"348","volume":"63","author":"K Hirasawa","year":"2003","unstructured":"Hirasawa K, Nishikawa SG, Norman KL, Coffey MC, Thompson BG, Yoon CS, et al: Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res. 2003, 63: 348-53.","journal-title":"Cancer Res"},{"key":"2716_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc969","volume":"3","author":"J Downward","year":"2003","unstructured":"Downward J: Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003, 3: 11-22. 10.1038\/nrc969.","journal-title":"Nat Rev Cancer"},{"key":"2716_CR8","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/sj.mt.6300403","volume":"16","author":"P Forsyth","year":"2008","unstructured":"Forsyth P, Roldan G, George D, Wallace C, Palmer CA, Morris D, et al: A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther. 2008, 16: 627-32. 10.1038\/sj.mt.6300403.","journal-title":"Mol Ther"},{"key":"2716_CR9","doi-asserted-by":"publisher","first-page":"7127","DOI":"10.1158\/1078-0432.CCR-08-0524","volume":"14","author":"L Vidal","year":"2008","unstructured":"Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, et al: A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res. 2008, 14: 7127-37. 10.1158\/1078-0432.CCR-08-0524.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"2716_CR10","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1038\/sj.bjc.6604595","volume":"99","author":"S Rowan","year":"2008","unstructured":"Rowan S, Rachet B, Alexe DM, Cooper N, Coleman MP: Survival from prostate cancer in England and Wales up to 2001. Br J Cancer. 2008, 99 (Suppl 1): S75-7.","journal-title":"Br J Cancer"},{"key":"2716_CR11","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004, 351: 1513-20. 10.1056\/NEJMoa041318.","journal-title":"N Engl J Med"},{"key":"2716_CR12","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004, 351: 1502-12. 10.1056\/NEJMoa040720.","journal-title":"N Engl J Med"},{"key":"2716_CR13","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1021\/jm00107a017","volume":"34","author":"F Gueritte-Voegelein","year":"1991","unstructured":"Gueritte-Voegelein F, Guenard D, Lavelle F, Le Goff MT, Mangatal L, Potier P: Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem. 1991, 34: 992-8. 10.1021\/jm00107a017.","journal-title":"J Med Chem"},{"key":"2716_CR14","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1021\/bi00062a003","volume":"32","author":"JF Diaz","year":"1993","unstructured":"Diaz JF, Andreu JM: Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry. 1993, 32: 2747-55. 10.1021\/bi00062a003.","journal-title":"Biochemistry"},{"key":"2716_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2165\/00003495-199855010-00002","volume":"55","author":"EA Eisenhauer","year":"1998","unstructured":"Eisenhauer EA, Vermorken JB, The taxoids: Comparative clinical pharmacology and therapeutic potential. Drugs. 1998, 55: 5-30. 10.2165\/00003495-199855010-00002.","journal-title":"Drugs"},{"key":"2716_CR16","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1128\/jvi.30.3.863-874.1979","volume":"30","author":"LE Babiss","year":"1979","unstructured":"Babiss LE, Luftig RB, Weatherbee JA, Weihing RR, Ray UR, Fields BN: Reovirus serotypes 1 and 3 differ in their in vitro association with microtubules. J Virol. 1979, 30: 863-74.","journal-title":"J Virol"},{"key":"2716_CR17","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1074\/jbc.M308637200","volume":"279","author":"J Kim","year":"2004","unstructured":"Kim J, Parker JS, Murray KE, Nibert ML: Nucleoside and RNA triphosphatase activities of orthoreovirus transcriptase cofactor mu2. J Biol Chem. 2004, 279: 4394-403.","journal-title":"J Biol Chem"},{"key":"2716_CR18","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1128\/JVI.01495-08","volume":"83","author":"T Kobayashi","year":"2009","unstructured":"Kobayashi T, Ooms LS, Chappell JD, Dermody TS: Identification of functional domains in reovirus replication proteins muNS and mu2. J Virol. 2009, 83: 2892-906. 10.1128\/JVI.01495-08.","journal-title":"J Virol"},{"key":"2716_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984, 22: 27-55.","journal-title":"Adv Enzyme Regul"},{"key":"2716_CR20","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S1470-2045(08)70107-4","volume":"9","author":"BH Park","year":"2008","unstructured":"Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, et al: Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008, 9: 533-42. 10.1016\/S1470-2045(08)70107-4.","journal-title":"Lancet Oncol"},{"key":"2716_CR21","doi-asserted-by":"publisher","first-page":"676","DOI":"10.4161\/cbt.8.8.7913","volume":"8","author":"J Chang","year":"2009","unstructured":"Chang J, Zhao X, Wu X, Guo Y, Guo H, Cao J, et al: A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers. Cancer Biol Ther. 2009, 8: 676-82. 10.4161\/cbt.8.8.7913.","journal-title":"Cancer Biol Ther"},{"key":"2716_CR22","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1091\/mbc.12.4.971","volume":"12","author":"NM Rusan","year":"2001","unstructured":"Rusan NM, Fagerstrom CJ, Yvon AM, Wadsworth P: Cell cycle-dependent changes in microtubule dynamics in living cells expressing green fluorescent protein-alpha tubulin. Mol Biol Cell. 2001, 12: 971-80.","journal-title":"Mol Biol Cell"},{"key":"2716_CR23","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","volume":"4","author":"MA Jordan","year":"1995","unstructured":"Jordan MA, Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Cancer. 1995, 4: 253-65. (2004)","journal-title":"Nat Rev Cancer"},{"key":"2716_CR24","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/0042-6822(78)90199-X","volume":"89","author":"MA McCrae","year":"1978","unstructured":"McCrae MA, Joklik WK: The nature of the polypeptide encoded by each of the 10 double-stranded RNA segments of reovirus type 3. Virology. 1978, 89: 578-93. 10.1016\/0042-6822(78)90199-X.","journal-title":"Virology"},{"key":"2716_CR25","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/0042-6822(78)90200-3","volume":"89","author":"TA Mustoe","year":"1978","unstructured":"Mustoe TA, Ramig RF, Sharpe AH, Fields BN: Genetics of reovirus: identification of the ds RNA segments encoding the polypeptides of the mu and sigma size classes. Virology. 1978, 89: 594-604. 10.1016\/0042-6822(78)90200-3.","journal-title":"Virology"},{"key":"2716_CR26","doi-asserted-by":"crossref","first-page":"8354","DOI":"10.1128\/JVI.72.10.8354-8357.1998","volume":"2","author":"L Brentano","year":"1998","unstructured":"Brentano L, Noah DL, Brown EG, Sherry B: The reovirus protein mu2, encoded by the M1 gene, is an RNA-binding protein. J Virol. 1998, 2: 8354-7. 7","journal-title":"J Virol"},{"key":"2716_CR27","first-page":"69","volume":"233","author":"KM Coombs","year":"1998","unstructured":"Coombs KM: Temperature-sensitive mutants of reovirus. Curr Top Microbiol Immunol. 1998, 233: 69-107.","journal-title":"Curr Top Microbiol Immunol"},{"key":"2716_CR28","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1128\/JVI.76.9.4483-4496.2002","volume":"76","author":"JS Parker","year":"2002","unstructured":"Parker JS, Broering TJ, Kim J, Higgins DE, Nibert ML: Reovirus core protein mu2 determines the filamentous morphology of viral inclusion bodies by interacting with and stabilizing microtubules. J Virol. 2002, 76: 4483-96. 10.1128\/JVI.76.9.4483-4496.2002.","journal-title":"J Virol"},{"key":"2716_CR29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1743-422X-1-6","volume":"1","author":"P Yin","year":"2004","unstructured":"Yin P, Keirstead ND, Broering TJ, Arnold MM, Parker JS, Nibert ML, et al: Comparisons of the M1 genome segments and encoded mu2 proteins of different reovirus isolates. Virol J. 2004, 1: 6-10.1186\/1743-422X-1-6.","journal-title":"Virol J"},{"key":"2716_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1476-4598-8-47","volume":"8","author":"S Sei","year":"2009","unstructured":"Sei S, Mussio JK, Yang QE, Nagashima K, Parchment RE, Coffey MC, et al: Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol Cancer. 2009, 8: 47-10.1186\/1476-4598-8-47.","journal-title":"Mol Cancer"},{"issue":"7","key":"2716_CR31","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/cgt.2009.10","volume":"16","author":"BJ Passer","year":"2009","unstructured":"Passer BJ, Castelo-Branco P, Buhrman JS, Varghese S, Rabkin SD, Martuza RL: Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells. Cancer Gene Ther. 2009, 16 (7): 551-60. 10.1038\/cgt.2009.10.","journal-title":"Cancer Gene Ther"},{"key":"2716_CR32","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/78638","volume":"6","author":"FR Khuri","year":"2000","unstructured":"Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, et al: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000, 6: 879-85. 10.1038\/78638.","journal-title":"Nat Med"},{"key":"2716_CR33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/sj.cgt.7701099","volume":"15","author":"SC Cheong","year":"2008","unstructured":"Cheong SC, Wang Y, Meng JH, Hill R, Sweeney K, Kirn D, et al: E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models. Cancer Gene Ther. 2008, 15: 40-50. 10.1038\/sj.cgt.7701099.","journal-title":"Cancer Gene Ther"},{"key":"2716_CR34","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1158\/1078-0432.CCR-08-1088","volume":"15","author":"AL Angelova","year":"2009","unstructured":"Angelova AL, Aprahamian M, Grekova SP, Hajri A, Leuchs B, Giese NA, et al: Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV. Clin Cancer Res. 2009, 15: 511-9. 10.1158\/1078-0432.CCR-08-1088.","journal-title":"Clin Cancer Res"},{"key":"2716_CR35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/sj.neo.7900016","volume":"1","author":"A Chahlavi","year":"1999","unstructured":"Chahlavi A, Todo T, Martuza RL, Rabkin SD: Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia. 1999, 1: 162-10.1038\/sj.neo.7900016.","journal-title":"Neoplasia"},{"key":"2716_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2174\/1566523044577988","volume":"4","author":"DE Post","year":"2004","unstructured":"Post DE, Fulci G, Chiocca EA, Van Meir EG: Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr Gene Ther. 2004, 4: 41-51. 10.2174\/1566523044577988.","journal-title":"Curr Gene Ther"},{"key":"2716_CR37","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.gassur.2005.06.024","volume":"9","author":"DP Eisenberg","year":"2005","unstructured":"Eisenberg DP, Adusumilli PS, Hendershott KJ, Yu Z, Mullerad M, Chan MK, et al: 5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. J Gastrointest Surg. 2005, 9: 1068-77. 10.1016\/j.gassur.2005.06.024. discussion 1077-9","journal-title":"J Gastrointest Surg"},{"key":"2716_CR38","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1089\/10430349950016410","volume":"10","author":"T Toyoizumi","year":"1999","unstructured":"Toyoizumi T, Mick R, Abbas AE, Kang EH, Kaiser LR, Molnar-Kimber KL: Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther. 1999, 10: 3013-29. 10.1089\/10430349950016410.","journal-title":"Hum Gene Ther"},{"key":"2716_CR39","doi-asserted-by":"publisher","first-page":"7050","DOI":"10.1128\/JVI.75.15.7050-7058.2001","volume":"75","author":"H Petrowsky","year":"2001","unstructured":"Petrowsky H, Roberts GD, Kooby DA, Burt BM, Bennett JJ, Delman KA, et al: Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus. J Virol. 2001, 75: 7050-8. 10.1128\/JVI.75.15.7050-7058.2001.","journal-title":"J Virol"},{"key":"2716_CR40","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4161\/cbt.5.1.2237","volume":"5","author":"PS Adusumilli","year":"2006","unstructured":"Adusumilli PS, Chan MK, Chun YS, Hezel M, Chou TC, Rusch VW, et al: Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. Cancer Biol Ther. 2006, 5: 48-53. 10.4161\/cbt.5.1.2237.","journal-title":"Cancer Biol Ther"},{"issue":"22","key":"2716_CR41","doi-asserted-by":"publisher","first-page":"5564","DOI":"10.1158\/1078-0432.CCR-10-1233","volume":"15;16","author":"C Comins","year":"2010","unstructured":"Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM, Vile R, Melcher A, Coffey MC, Mettinger KL, Nuovo G, Cohn DE, Phelps M, Harrington KJ, Pandha HS: REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer. Clin Cancer Res. 2010, 15;16 (22): 5564-5572.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"2716_CR42","doi-asserted-by":"publisher","first-page":"6158","DOI":"10.1158\/1078-0432.CCR-09-0796","volume":"15","author":"HS Pandha","year":"2009","unstructured":"Pandha HS, Heinemann L, Simpson GR, Melcher A, Prestwich R, Errington F, Coffey M, Harrington KJ, Morgan R: Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res. 2009, 15 (19): 6158-66. 10.1158\/1078-0432.CCR-09-0796.","journal-title":"Clin Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-11-221\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T20:25:12Z","timestamp":1630614312000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-11-221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,6]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["2716"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-11-221","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,6]]},"assertion":[{"value":"29 November 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"221"}}